Navigation Links
Press Statement Issued by Ranbaxy Laboratories Limited
Date:2/25/2009

GURGAON, India, Feb. 25 /PRNewswire/ -- Ranbaxy has just received a letter and information indicating that all pending and approved ANDAs from Ranbaxy's Paonta Sahib facility have been added to a list maintained under a policy entitled "Application Integrity Policy" or "AIP". Ranbaxy will analyze the letter and other information fully and respond appropriately in a timely manner.

The FDA has said it has no evidence the drugs on the market are substandard and also that they comply with specifications upon testing.

No products from Ranbaxy's other manufacturing facilities are included in the AIP.

Ranbaxy will continue to co-operate with the USFDA. Further, no effort or action will be spared to timely protect key ANDAs from Paonta Sahib, which include some First to File applications.

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies," resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 11 countries.

    Company Contacts for Media:

    India Contacts:

    Ramesh L. Adige
    President - Corporate Affairs and Global Corporate Communications
    Ranbaxy Laboratories Ltd.
    Plot 90, Sector 32, Gurgaon
    Haryana122001, India
    Tel: +91-124-4135000
    e-mail: ramesh.adige@ranbaxy.com

    or

    Raghu Kochar
    Director - Corporate Communications
    Ranbaxy Laboratories Ltd.
    Plot 90, Sector 32, Gurgaon
    Haryana122001, India
    Tel: +91-124-4135141 / Mob: 9811617256
    e-mail: raghu.kochar@ranbaxy.com

    or

    Krishnan Ramalingam
    Sr. Manager - Corporate Communications
    Ranbaxy Laboratories Ltd.
    Plot 90, Sector 32, Gurgaon
    Haryana122001, India
    Tel: +91-124-4135143 / Mob: 9810042540
    e-mail: krishnan.ramalingam@ranbaxy.com

    USA Contact:

    Charles M. Caprariello
    Vice President, Corporate Communications
    Ranbaxy Inc.
    (609) 720-5615
    email : chuck.caprariello@ranbaxy.com


'/>"/>
SOURCE Ranbaxy Laboratories Limited
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Fluctuating eye pressure associated with visual field deterioration in glaucoma patients
2. Children of depressed moms do better when dad is involved, SLU researcher finds
3. Clinical depression linked to abnormal emotional brain circuits
4. Tumors use enzyme to recruit regulatory T-cells and suppress immune response
5. Specific antagonism lowers blood pressure
6. Are too many people diagnosed as depressed?
7. Depression Taking Toll on Returning U.S. Vets
8. Doctors Often Miss High Blood Pressure in Kids
9. Pill box organizers increase HIV patients adherence and improve viral suppression
10. Damp, Moldy Homes May Cause Depression
11. Treating depression may improve recovery of heart rate variability following coronary syndromes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... 05, 2016 , ... The event is being held on April 7, 2016 ... Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research for the care and ... Parkinson’s disease and is the architect of this informative event to raise awareness and ...
(Date:2/5/2016)... ... February 05, 2016 , ... Looking for a last-minute ... at the tips of your toes. Foot massage, whether administered by a professional masseuse ... and relaxation. The American Board of Multiple Specialties in Podiatry (ABMSP) has ...
(Date:2/5/2016)... ... 2016 , ... The Lymphoma Research Foundation (LRF) – the ... the lymphoma community through a comprehensive series of education programs, outreach initiatives and ... Event at the La Gorce Country Club in Miami Beach on March 15, ...
(Date:2/5/2016)... Grants Pass, OR (PRWEB) , ... February 05, 2016 , ... ... though, with modern technology, such water may be safer than regular municipal or well ... water advocate and radio host Sharon Kleyne, could go a long way toward increasing ...
(Date:2/5/2016)... ... February 05, 2016 , ... Boar’s Head Brand®, one ... time for this weekend’s Big Game. Take the stress out of your party preparation ... your guests happy at every stage of the game. , “The key to hosting ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... 4, 2016  Edwards Lifesciences Corporation (NYSE: EW ... heart disease and critical care monitoring, announced today that ... agreement with Morgan Stanley & Co. LLC to repurchase ... part of the Company,s previously authorized program to repurchase ... --> --> ...
(Date:2/4/2016)... Wegener Polyangiitis - Pipeline Review, H2 ... Polyangiitis - Pipeline Review, H2 2015, provides an ... This report provides comprehensive information on the therapeutic ... at various stages, therapeutics assessment by drug target, ... and molecule type, along with latest updates, and ...
(Date:2/4/2016)... Feb. 4, 2016  Omnicell, Inc. (NASDAQ: OMCL ), ... to healthcare systems, today announced results for its fiscal ... --> --> GAAP results: Revenue ... up $5.1 million or 4.1% from the third quarter ... the fourth quarter of 2014. Revenue for the year ...
Breaking Medicine Technology: